Skip to main content

Penumbra, Inc. (PEN) Stock Analysis

HoldModerate Confidence

Healthcare · Medical Devices

Earnings in 1 day (2026-05-01). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $324.84, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining.

Penumbra is a medical device company focused on thrombectomy (blood clot removal) for ischemic stroke, pulmonary embolism, and acute limb ischemia, generating $1.4B revenue in 2025 (+17.5% YoY). Revenue comes from CAVT systems, catheters, and accessories sold to specialist... Read more

$324.84+6.5% A.UpsideScore 5.7/10#8 of 40 Medical Devices
Entry $308.59(5% below current)Stop $302.81Target $328.50(resistance)A.R:R -0.1:1Setup A.R:R 3.4:1
Analyst target$365.79+12.6%14 analysts
$328.50our TP
$324.84price
$365.79mean
$374

Hold if already holding. Not a fresh buy at $324.84, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Downgraded from BUY WAIT — price $324.83 has reached target $328.50. No upside to wait for. Score 5.7/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: moderate.

Val4.1Qual6.2Grw8.8Mom2.5Sent5.7Ins5.0Peer3.8Tech9.0Risk6.75.7OVERALL

Thesis

Rewards
No bull case signals
Risks
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)72.0
P/E (Fwd)50.9
Mkt Cap$12.7B
EV/EBITDA60.1
Profit Mgn12.7%
ROE13.8%
Rev Growth22.1%
Beta0.84
DividendNone
Rating analysts22

Quality Signals

Piotroski F9/9

Options Flow

P/C2.29bearish
IV47%normal
Max Pain$410+26.2% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMProductlimited number of product families
    10-K Item 1A: 'We have generated most of our revenue and revenue growth from a limited number of product families.'
  • MEDIUMSuppliersingle or limited number of suppliers
    10-K Item 1A: 'For reasons of quality assurance, cost effectiveness or availability, we typically procure certain raw materials and components from a single or limited number of suppliers.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·2 ceiling hits

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
4.0
Rsi
7.5
Uptrend pullback (RSI 40) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.6
Quality Rank
6.7
Growth Rank
8.0
GatesMomentum 2.5<4.5A.R:R -0.1=NEGATIVEEARNINGS PROXIMITY 1d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $323.71Resistance $335.20

Price Targets

$303
$309
$329
A.Upside+1.1%
A.R:R-0.1:1
Setup A.R:R (at entry)3.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-2.0% upside)
! Earnings in 1 day - binary event risk
! Momentum score 2.5/10 — below 4.5 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-01 (1d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PEN stock a buy right now?

Hold if already holding. Not a fresh buy at $324.84, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Downgraded from BUY WAIT — price $324.83 has reached target $328.50. No upside to wait for. Target $328.50 (+1.1%), stop $302.81 (−7.3%), A.R:R -0.1:1. Score 5.7/10, moderate confidence.

What is the PEN stock price target?

Take-profit target: $328.50 (+6.5% upside). Target $328.50 (+1.1%), stop $302.81 (−7.3%), A.R:R -0.1:1. Stop-loss: $302.81.

What are the risks of investing in PEN?

Analyst target reached - limited upside remaining.

Is PEN overvalued or undervalued?

Penumbra, Inc. trades at a P/E of 72.0 (forward 50.9). TrendMatrix value score: 4.1/10. Verdict: Hold.

What do analysts say about PEN?

22 analysts cover PEN with a consensus score of 3.5/5. Average price target: $366.

What does Penumbra, Inc. do?Penumbra is a medical device company focused on thrombectomy (blood clot removal) for ischemic stroke, pulmonary...

Penumbra is a medical device company focused on thrombectomy (blood clot removal) for ischemic stroke, pulmonary embolism, and acute limb ischemia, generating $1.4B revenue in 2025 (+17.5% YoY). Revenue comes from CAVT systems, catheters, and accessories sold to specialist physicians via a direct sales force in the US, Europe, Canada, Australia, and Singapore. On January 14, 2026, Penumbra entered a merger agreement with Boston Scientific at $374/share (~$14.5B enterprise value).

Related stocks: GMED (Globus Medical, Inc.) · TMDX (TransMedics Group, Inc.) · INSP (Inspire Medical Systems, Inc.) · PODD (Insulet Corporation) · SNN (Smith & Nephew SNATS, Inc.)